Toxicity of the high-dose chemotherapy CTC regimen (cyclophosphamide, thiotepa, carboplatin): the Netherlands Cancer Institute experience

di Schrama, J G, Holtkamp, M J, Baars, J W, Schornagel, J H, Rodenhuis, S
Pubblicazione 2003

Evaluating the quality of life of cancer patients: assessments by patients, significant others, physicians and nurses

di Sneeuw, K C A, Aaronson, N K, Sprangers, M A G, Detmar, S B, Wever, L D V, Schornagel, J H
Pubblicazione 1999

Efficacy of up-front 5-fluorouracil-epidoxorubicin-cyclophosphamide (FEC) chemotherapy with an increased dose of epidoxorubicin in high-risk breast cancer patients.

di van der Wall, E., Rutgers, E. J., Holtkamp, M. J., Baars, J. W., Schornagel, J. H., Peterse, J. L., Beijnen, J. H., Rodenhuis, S.
Pubblicazione 1996

Determinants of the elimination of methotrexate and 7-hydroxy-methotrexate following high-dose infusional therapy to cancer patients

di Joerger, M, Huitema, A D R, van den Bongard, H J G D, Baas, P, Schornagel, J H, Schellens, J H M, Beijnen, J H
Pubblicazione 2006

Phase II and pharmacological study of oral paclitaxel (Paxoral) plus ciclosporin in anthracycline-pretreated metastatic breast cancer

di Helgason, H H, Kruijtzer, C M F, Huitema, A D R, Marcus, S G, ten Bokkel Huinink, W W, Schot, M E, Schornagel, J H, Beijnen, J H, Schellens, J H M
Pubblicazione 2006